GMAB

GMAB

GMAB

Letters With This Ticker

Quarter	Letter Date	Fund Name	QTD	YTD	Tickers	Keywords/Themes	Theme Commentary	Pitches	Letter
2025 Q4	Dec 31, 2025	Orbis Global Equity	0.0%	0.0%	GMAB, GOOGL, ITUB, NXT.L, QXO	AI, global, long-term, management, technology, value	The manager discusses the AI revolution's impact on Alphabet, noting how Gemini 3 has overtaken ChatGPT in capability and is catching up in user numbers. Alphabet's competitive advantages in AI include seamless integration between Google Search and Gemini, unique data access through YouTube and Android, and cost advantages through vertical integration with cloud infrastructure and custom chips.		View
2025 Q4	Dec 31, 2025	Orbis International Equity	0.0%	0.0%	GMAB, ICLR, IMX, J36.SI, PRU.L	Biotech, Bottom-up, Entertainment, global, international, value	Biotech has become an especially fruitful hunting ground following the epic bust after COVID boom. The sector typically suffers from structural overvaluation but rising rates, geopolitical noise around drug pricing, and capital draw towards AI has created opportunities to acquire innovative businesses at less than present value of marketed drugs. The theatrical window remains key to maximizing IP value as content gains powerful halo effect from theatre runs while being cash-flow generative. Recent bidding war for Warner Bros Discovery highlights immense value placed on scarce content and platforms for developing high-value IP. Portfolio has naturally shifted to more typical collection of idiosyncratic bottom-up investments as post-pandemic dislocations normalized. Focus remains on finding businesses priced significantly less than intrinsic worth through deep fundamental analysis.		View
2024 Q4	Dec 31, 2024	Harding Loevner International Equity	-	1.8%	6146 JP, ADYEN NA, GMAB, OR FP, TSM	-			View
2025 Q3	Oct 8, 2025	Orbis Global Equity	-	-	ALNY, CRSP, GMAB, INSM	Biotechnology, Gene Therapy, healthcare, innovation, Value Investing	Orbis highlights the structural shift toward domestic consumption in Asia as export-led growth models unwind. The fund identifies undervalued consumer-oriented franchises benefiting from rising incomes and local demand. Consumption-driven growth remains a long-duration opportunity as economic rebalancing unfolds.	CRSP INSM GMAB DC ALNY	View
2025 Q3	Oct 13, 2025	The Baird Chautauqua International Growth Fund	5.2%	19.0%	6160 HK, ADYEN NA, BABA, CSU, GMAB, TCS IN	Artificial Intelligence, emerging markets, Global Growth, healthcare, valuation	The fund reports moderate returns driven by resilient performance in technology and consumer sectors, while maintaining exposure to long-term structural growth themes in AI adoption and healthcare innovation. Managers emphasize disciplined valuation and high-quality companies across Europe and Asia despite macro uncertainty.		View
2025 Q4	Jan 20, 2026	Harding Loevner Global Equity	1.9%	12.7%	0700.HK, 1299.HK, 2308.TW, 300124.SZ, 300760.SZ, 4519.T, 6758.T, 6861.T, ABBV, ACN, ADBE, ALFA.ST, AME, AMZN, APH, ASML, ATCO-A.ST, ATD.TO, ATKR, AVGO, BKNG, CME, COMP.L, CSGP, D05.SI, DE, DHR, DPLM.L, EFX, ELV, EPI-A.ST, FN, GMAB, GOOGL, HDFCBANK.NS, HEI, HLN.L, HON, JNJ, META, MSFT, NFLX, NOC, NVDA, PGR, ROG.SW, SAP, SGSN.SW, SHEL, SLB, SU.PA, TMO, TSM, TTD, TW, V, VRTX, WMMVY	AI, global, international, semiconductors, technology, value	AI represents a capital-expenditure regime with two distinct camps: hyperscalers investing in computing capacity and physical enablers of the buildout. The US market is more dependent on AI continuing to surprise to the upside due to richer valuations and concentrated exposure. Global semiconductor ecosystem enables AI buildout, spanning chip foundries, memory-chip makers, and equipment manufacturers. International markets are more heavily tilted toward this manufacturing and infrastructure provider segment. International markets trade at roughly half the multiples of US stocks, offering more attractive valuations. Non-US markets start from cheaper valuations and possess more diverse growth opportunities unrelated to AI.	GOOG	View
2022 Q4	Jan 20, 2023	Artisan Global Discovery	7.6%	13.1%	0ABI LN, 0I4Q LN, CNHI, CTLT, GMAB, GXI GR, IR, LSCC, MPWR, PUMA, RYTM, SAIA, SIVB, TEAM, ZS	-			View

Pitches With This Ticker

Date	Pitch Type	Author	Company	Industry	Sub Industry	Bull / Bear	Stock Exchange	Keywords	Action
Jan 27, 2026	Fund Letters	Timo Smuts	Genmab A/S	Health Care	Biotechnology	Bull	NASDAQ	Biotech, Optionality, Patentcliff, pipeline, R&D	View Pitch

BSD Shareholders of GMAB

This report provides a detailed summary of investor holdings for a specified stock ticker, highlighting key metrics such as fund name, total assets under management (AUM), invested value, portfolio weight, and shares owned. It also tracks changes in share ownership during the last quarter, including the percentage of shares bought or sold and the percentage of outstanding shares owned. The data is generated using an API that processes investor holdings and calculates these values for each fund. This report helps investors and analysts monitor the stock positions of major funds, identify investment trends, and assess the influence of large investors on individual stocks.

Filing Date: September 30, 2025

Manager Name	Fund Name	Fund AUM	Invested Value	Portfolio Weight	Shares Owned	Shares Bought / Sold During Quarter	% Bought / Sold During Quarter	% of Shares Outstanding Owned
No investor data available.

Join for free and get access to the buyside

Get insights from the world's most influential hedge fund investors direct to your inbox

Follow Us On: